IL-17A and TNF-α Inhibitors Induce Multiple Molecular Changes in Psoriasis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 9

PMID 36483564

Authors

Qiang Dong

Dan Li

Bi Bo Xie

Li Hua Hu

Jia Huang

Xiao Xiao Jia

Yan Li Tang

Gan Hong Liu

Ning Ning Shen

Xiao Bing Yu

Affiliations

Soon will be listed here.

Abstract

Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psoriatic lesions from patients treated with these drugs using data-independent acquisition mass spectrometry (DIA-MS). Thousands of differentially expressed proteins (DEPs) changed over 12 weeks of treatment. Network analysis showed that DEPs could interact and induce transformation in matrix components, metabolic regulation, and immune response. The results of parallel reaction monitoring (PRM) analysis suggested that S100s, STAT1, KRT2, TYMP, SOD2, HSP90AB1, TFRC, and COL5A1 were the most significantly changed proteins in both groups. There was a positive association between the Psoriasis Area and Severity Index (PASI) score and three proteins (TFRC, IMPDH2, KRT2). Our study findings suggest that inhibition of IL-17A and TNF-α can induce changes in multiple molecules in psoriatic lesions and have an overlapping influence on the immune response and process through direct or indirect effects.

Citing Articles

Risk factors of primary liver cancer initiation associated with tumour initiating cell emergence: novel targets for promising preventive therapies.

Brouillet A, Lafdil F eGastroenterology. 2025; 1(1):e100010.

PMID: 39944247 PMC: 11770463. DOI: 10.1136/egastro-2023-100010.

Cross-sectional study of proteomic differences between moderate and severe psoriasis.

Wu L, Cen C, Xie B, Hu L, Huang J, Shen N Sci Rep. 2025; 15(1):3387.

PMID: 39870771 PMC: 11772871. DOI: 10.1038/s41598-025-87252-9.

Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies.

Morgner B, Werz O, Wiegand C, Tittelbach J Commun Biol. 2024; 7(1):1529.

PMID: 39558145 PMC: 11574237. DOI: 10.1038/s42003-024-07226-x.

Discovery of PANoptosis-related signatures correlates with immune cell infiltration in psoriasis.

Wu L, Jiao X, Jing M, Zhang S, Wang Y, Li C PLoS One. 2024; 19(10):e0310362.

PMID: 39480805 PMC: 11527320. DOI: 10.1371/journal.pone.0310362.

Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression.

Tiuca O, Morariu S, Mariean C, Tiuca R, Nicolescu A, Cotoi O Life (Basel). 2024; 14(1).

PMID: 38255729 PMC: 10820213. DOI: 10.3390/life14010114.

References

Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y . In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019; 9(9):2475-2488. PMC: 6526001. DOI: 10.7150/thno.31144. View

Gerdes S, Pinter A, Papavassilis C, Reinhardt M . Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2019; 34(3):533-541. PMC: 7065121. DOI: 10.1111/jdv.16004. View

Sutaria N, Au S . Failure rates and survival times of systemic and biologic therapies in treating psoriasis: a retrospective study. J Dermatolog Treat. 2019; 32(6):617-620. DOI: 10.1080/09546634.2019.1688756. View

Pappireddi N, Martin L, Wuhr M . A Review on Quantitative Multiplexed Proteomics. Chembiochem. 2019; 20(10):1210-1224. PMC: 6520187. DOI: 10.1002/cbic.201800650. View

Hu Y, Pan Z, Hu Y, Zhang L, Wang J . Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease. Mol Neurobiol. 2016; 54(6):4452-4465. DOI: 10.1007/s12035-016-9998-8. View

Armstrong A, Read C . Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. DOI: 10.1001/jama.2020.4006. View

Amin M, No D, Egeberg A, Wu J . Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. Am J Clin Dermatol. 2017; 19(1):1-13. DOI: 10.1007/s40257-017-0328-3. View

Armstrong A, Puig L, Joshi A, Skup M, Williams D, Li J . Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020; 156(3):258-269. PMC: 7042876. DOI: 10.1001/jamadermatol.2019.4029. View

Ernst J, Bar-Joseph Z . STEM: a tool for the analysis of short time series gene expression data. BMC Bioinformatics. 2006; 7:191. PMC: 1456994. DOI: 10.1186/1471-2105-7-191. View

10.

Escoda-Ferran C, Carrasco E, Caballero-Banos M, Miro-Julia C, Martinez-Florensa M, Consuegra-Fernandez M . Modulation of CD6 function through interaction with Galectin-1 and -3. FEBS Lett. 2014; 588(17):2805-13. DOI: 10.1016/j.febslet.2014.05.064. View

11.

Urbano P, Aguirre-Gamboa R, Ashikov A, van Heeswijk B, Krippner-Heidenreich A, Tijssen H . TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression. J Allergy Clin Immunol. 2017; 142(2):517-529. DOI: 10.1016/j.jaci.2017.11.024. View

12.

Prassas I, Eissa A, Poda G, Diamandis E . Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015; 14(3):183-202. DOI: 10.1038/nrd4534. View

13.

Navrazhina K, Frew J, Grand D, Williams S, Hur H, Gonzalez J . Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol. 2022; 187(2):223-233. PMC: 9356983. DOI: 10.1111/bjd.21060. View

14.

Kolbinger F, Loesche C, Valentin M, Jiang X, Cheng Y, Jarvis P . β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2016; 139(3):923-932.e8. DOI: 10.1016/j.jaci.2016.06.038. View

15.

Egeberg A, Ottosen M, Gniadecki R, Broesby-Olsen S, Dam T, Bryld L . Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2017; 178(2):509-519. DOI: 10.1111/bjd.16102. View

16.

Matsunaga Y, Hashimoto Y, Ishiko A . Stratum corneum levels of calprotectin proteins S100A8/A9 correlate with disease activity in psoriasis patients. J Dermatol. 2021; 48(10):1518-1525. DOI: 10.1111/1346-8138.16032. View

17.

Silfvast-Kaiser A, Paek S, Menter A . Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2018; 19(1):45-54. DOI: 10.1080/14712598.2019.1555235. View

18.

Bolt J, van Kuijk A, Teunissen M, van der Coelen D, Aarrass S, Gerlag D . Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines. 2022; 10(2). PMC: 8869729. DOI: 10.3390/biomedicines10020324. View

19.

Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q . Multi-organ proteomic landscape of COVID-19 autopsies. Cell. 2021; 184(3):775-791.e14. PMC: 7794601. DOI: 10.1016/j.cell.2021.01.004. View

20.

Koch M, Kockmann T, Rodriguez E, Wehkamp U, Hiebert P, Ben-Yehuda Greenwald M . Quantitative Proteomics Identifies Reduced NRF2 Activity and Mitochondrial Dysfunction in Atopic Dermatitis. J Invest Dermatol. 2022; 143(2):220-231.e7. DOI: 10.1016/j.jid.2022.08.048. View